# Rare FOIA Exemptions — Eyeball Report

Every occurrence of the 5 rarely-used exemption types across all five modules. **537 occurrences across 79 file–marker combinations** (a single file may appear in multiple sections if it uses more than one rare type).

The dominant `(b)(4)` (trade secrets) and `(b)(6)` (personal privacy) markers are excluded — see `data/exemptions_report.md` for those.

Each row links to the file on PHMPT (the original source; clicking opens the PDF in your browser — phmpt.org may show a one-time Cloudflare challenge) and on ICAN (re-host, usually loads directly).

---

## `(b)(7)(C)` — Law enforcement records — personal privacy

**302 occurrence(s) across 2 file(s).**

| File | Module | Company | License | Pages | Links |
| --- | --- | --- | --- | --- | --- |
| `116_BLA-125742-0_08-21-2021_Inspection-Related_Establi.pdf` | Individual | Pfizer | — | 7-8, 11-23, 25, 27-41, 43-44, 46-55, 58-61, 63-71, 75-79 *(×153 hits)* | [PHMPT](https://phmpt.org/wp-content/uploads/2023/11/116_BLA-125742-0_08-21-2021_Inspection-Related_Establi.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/11/116_BLA-125742-0_08-21-2021_Inspection-Related_Establi.pdf) |
| `92_BLA-125742-0_08-19-2021_Inspection-Related_Inspect.pdf` | Individual | Pfizer | — | 3, 6-12, 15-27, 29-31, 33-39, 47, 53-56, 58, 65, 71, 75-77 *(×149 hits)* | [PHMPT](https://phmpt.org/wp-content/uploads/2023/11/92_BLA-125742-0_08-19-2021_Inspection-Related_Inspect.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/11/92_BLA-125742-0_08-19-2021_Inspection-Related_Inspect.pdf) |

## `(b)(1)` — Classified information

**86 occurrence(s) across 24 file(s).**

| File | Module | Company | License | Pages | Links |
| --- | --- | --- | --- | --- | --- |
| `94_BLA-125752-0_01-26-2022_Memo_Other.pdf` | Individual | Moderna | — | 1-2 | [PHMPT](https://phmpt.org/wp-content/uploads/2025/05/94_BLA-125752-0_01-26-2022_Memo_Other.pdf) |
| `032-Appendix-in-Support-filed-by-Public-Health-and-Medical-Professionals-for-Transparency-re-31-Reply.pdf` | Individual | Pfizer | — | 70 | [PHMPT](https://phmpt.org/wp-content/uploads/2021/12/032-Appendix-in-Support-filed-by-Public-Health-and-Medical-Professionals-for-Transparency-re-31-Reply.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2022/03/032-Appendix-in-Support-filed-by-Public-Health-and-Medical-Professionals-for-Transparency-re-31-Reply.pdf) |
| `111521-Second-Joint-Status-Report.pdf` | Individual | Pfizer | — | 2 | [PHMPT](https://phmpt.org/wp-content/uploads/2021/11/111521-Second-Joint-Status-Report.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2022/03/111521-Second-Joint-Status-Report.pdf) |
| `125742_S66_M1_pp-cvv-usa-0357.pdf` | M1 | Pfizer | BLA | 8, 12, 23, 26, 32, 44, 72, 91, 113, 115-117, 120-125, 127-133, 144, 148 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/08/125742_S66_M1_pp-cvv-usa-0357.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/08/125742_S66_M1_pp-cvv-usa-0357.pdf) |
| `125742_S65_M1_pp-cvv-usa-0349-01.pdf` | M1 | Pfizer | BLA | 20, 47, 57, 60-62, 69, 79, 84, 86-90 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/08/125742_S65_M1_pp-cvv-usa-0349-01.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/08/125742_S65_M1_pp-cvv-usa-0349-01.pdf) |
| `125742_S117_M1_pp-cvv-usa-0422.pdf` | M1 | Pfizer | BLA | 3, 6, 16 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/08/125742_S117_M1_pp-cvv-usa-0422.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/08/125742_S117_M1_pp-cvv-usa-0422.pdf) |
| `125742_S141_M1_pp-cvv-usa-0473.pdf` | M1 | Pfizer | BLA | 3-5 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/08/125742_S141_M1_pp-cvv-usa-0473.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/08/125742_S141_M1_pp-cvv-usa-0473.pdf) |
| `125742_S116_M1_pp-cvv-usa-0387.pdf` | M1 | Pfizer | BLA | 1, 4 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/08/125742_S116_M1_pp-cvv-usa-0387.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/08/125742_S116_M1_pp-cvv-usa-0387.pdf) |
| `125742_S116_M1_pp-cvv-usa-0389.pdf` | M1 | Pfizer | BLA | 1, 3 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/08/125742_S116_M1_pp-cvv-usa-0389.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/08/125742_S116_M1_pp-cvv-usa-0389.pdf) |
| `125742_S118_M1_pp-cvv-usa-0426.pdf` | M1 | Pfizer | BLA | 1, 4 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/08/125742_S118_M1_pp-cvv-usa-0426.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/08/125742_S118_M1_pp-cvv-usa-0426.pdf) |
| `125742_S129_M1_pp-cvv-usa-0442.pdf` | M1 | Pfizer | BLA | 2, 4 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/08/125742_S129_M1_pp-cvv-usa-0442.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/08/125742_S129_M1_pp-cvv-usa-0442.pdf) |
| `125742_S131_M1_pp-cvv-usa-0391.pdf` | M1 | Pfizer | BLA | 1, 6 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/08/125742_S131_M1_pp-cvv-usa-0391.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/08/125742_S131_M1_pp-cvv-usa-0391.pdf) |
| `125742_S131_M1_pp-cvv-usa-0432.pdf` | M1 | Pfizer | BLA | 1, 5 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/08/125742_S131_M1_pp-cvv-usa-0432.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/08/125742_S131_M1_pp-cvv-usa-0432.pdf) |
| `125742_S88_M1_pp-cvv-usa-0378.pdf` | M1 | Pfizer | BLA | 1, 4 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/08/125742_S88_M1_pp-cvv-usa-0378.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/08/125742_S88_M1_pp-cvv-usa-0378.pdf) |
| `125742_S94_M1_pp-cvv-usa-0408.pdf` | M1 | Pfizer | BLA | 4, 21 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/08/125742_S94_M1_pp-cvv-usa-0408.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/08/125742_S94_M1_pp-cvv-usa-0408.pdf) |
| `27034_S24_M1_thermal-shipping-instructions.pdf` | M1 | Pfizer | EUA | 1 *(×2 hits)* | [PHMPT zip](https://p1215data0612.s3.us-east-2.amazonaws.com/pdocs/multiple/pd-eua-production-051925.zip) |
| `125742_S123_M1_pp-cvv-usa-0430.pdf` | M1 | Pfizer | BLA | 16 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/08/125742_S123_M1_pp-cvv-usa-0430.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/08/125742_S123_M1_pp-cvv-usa-0430.pdf) |
| `125742_S1_M1_356h.pdf` | M1 | Pfizer | BLA | 1 | [PHMPT](https://phmpt.org/wp-content/uploads/2022/03/125742_S1_M1_356h.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2022/03/125742_S1_M1_356h.pdf) |
| `125742_S2_M1_356h.pdf` | M1 | Pfizer | BLA | 1 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/10/125742_S2_M1_356h.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/10/125742_S2_M1_356h.pdf) |
| `125752_S3_M5_5314_eua-roche-elecsys-ifu.pdf` | M5 | Moderna | BLA | 3, 20, 23 *(×6 hits)* | [PHMPT](https://phmpt.org/wp-content/uploads/2024/11/125752_S3_M5_5314_eua-roche-elecsys-ifu.pdf) |
| `19745_S73_M5_5314_21120-517-report.pdf` | M5 | Moderna | EUA | 12 *(×2 hits)* | [PHMPT zip](https://mdata0612.s3.us-east-2.amazonaws.com/mdocs/multiple/md-eua-010226.zip) |
| `19745_S73_M5_5314_21120-578-approved.pdf` | M5 | Moderna | EUA | 7 *(×2 hits)* | [PHMPT zip](https://mdata0612.s3.us-east-2.amazonaws.com/mdocs/multiple/md-eua-010226.zip) |
| `19745_S73_M5_5314_21120-705-report.pdf` | M5 | Moderna | EUA | 37 *(×2 hits)* | [PHMPT zip](https://mdata0612.s3.us-east-2.amazonaws.com/mdocs/multiple/md-eua-010226.zip) |
| `19745_S73_M5_5314_21120-9152-report.pdf` | M5 | Moderna | EUA | 10 *(×2 hits)* | [PHMPT zip](https://mdata0612.s3.us-east-2.amazonaws.com/mdocs/multiple/md-eua-010226.zip) |

## `(b)(5)` — Deliberative process / attorney privilege

**62 occurrence(s) across 15 file(s).**

| File | Module | Company | License | Pages | Links |
| --- | --- | --- | --- | --- | --- |
| `032-Appendix-in-Support-filed-by-Public-Health-and-Medical-Professionals-for-Transparency-re-31-Reply.pdf` | Individual | Pfizer | — | 129-130, 137-138 *(×15 hits)* | [PHMPT](https://phmpt.org/wp-content/uploads/2021/12/032-Appendix-in-Support-filed-by-Public-Health-and-Medical-Professionals-for-Transparency-re-31-Reply.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2022/03/032-Appendix-in-Support-filed-by-Public-Health-and-Medical-Professionals-for-Transparency-re-31-Reply.pdf) |
| `108_BLA-125742-0_08-21-2021_Inspection-Related_Inspect.pdf` | Individual | Pfizer | — | 3, 6, 10, 12, 14, 18-19 *(×12 hits)* | [PHMPT](https://phmpt.org/wp-content/uploads/2023/11/108_BLA-125742-0_08-21-2021_Inspection-Related_Inspect.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/11/108_BLA-125742-0_08-21-2021_Inspection-Related_Inspect.pdf) |
| `93_BLA-125752-0_01-26-2022_Inspection-Related_Inspect.pdf` | Individual | Moderna | — | 1-4, 6-7 *(×10 hits)* | [PHMPT](https://phmpt.org/wp-content/uploads/2025/05/93_BLA-125752-0_01-26-2022_Inspection-Related_Inspect.pdf) |
| `120_Courtesy-Copy_BLA-125742-0_CBER-CMC-BLA-Review-Memo-COMIRNATY.pdf` | Individual | Pfizer | — | 11, 50, 66, 124 *(×6 hits)* | [PHMPT](https://phmpt.org/wp-content/uploads/2023/11/120_Courtesy-Copy_BLA-125742-0_CBER-CMC-BLA-Review-Memo-COMIRNATY.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/11/120_Courtesy-Copy_BLA-125742-0_CBER-CMC-BLA-Review-Memo-COMIRNATY.pdf) |
| `100A_BLA-125742-0_08-20-2021_Memo_Other.pdf` | Individual | Pfizer | — | 3 *(×3 hits)* | [PHMPT](https://phmpt.org/wp-content/uploads/2023/11/100A_BLA-125742-0_08-20-2021_Memo_Other.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/11/100A_BLA-125742-0_08-20-2021_Memo_Other.pdf) |
| `100_BLA-125742-0_08-20-2021_Memo_Other.pdf` | Individual | Pfizer | — | 3 *(×3 hits)* | [PHMPT](https://phmpt.org/wp-content/uploads/2023/11/100_BLA-125742-0_08-20-2021_Memo_Other.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/11/100_BLA-125742-0_08-20-2021_Memo_Other.pdf) |
| `118_1_BLA-125742-0_08-22-2021_Inspection-Related_Inspect.pdf` | Individual | Pfizer | — | 1 *(×2 hits)* | [PHMPT](https://phmpt.org/wp-content/uploads/2023/11/118_1_BLA-125742-0_08-22-2021_Inspection-Related_Inspect.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/11/118_1_BLA-125742-0_08-22-2021_Inspection-Related_Inspect.pdf) |
| `125742-45_05-06-2022_Meeting-Summary_Committee.pdf` | Individual | Pfizer | — | 4 *(×2 hits)* | [PHMPT](https://phmpt.org/wp-content/uploads/2024/01/125742-45_05-06-2022_Meeting-Summary_Committee.pdf) |
| `027-Appendix-in-Support-filed-by-Public-Health-and-Medical-Professionals-for-Transparency-re-26-Brief-Memorandum-in-Support-of-Motion.pdf` | Individual | Pfizer | — | 605 | [PHMPT](https://phmpt.org/wp-content/uploads/2021/12/027-Appendix-in-Support-filed-by-Public-Health-and-Medical-Professionals-for-Transparency-re-26-Brief-Memorandum-in-Support-of-Motion.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2022/03/027-Appendix-in-Support-filed-by-Public-Health-and-Medical-Professionals-for-Transparency-re-26-Brief-Memorandum-in-Support-of-Motion.pdf) |
| `109_Courtesy-Copy_2_BLA-125742-0_CMC-Review-Memo-August-21-2021-COMIRNATY.pdf` | Individual | Pfizer | — | 52 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/11/109_Courtesy-Copy_2_BLA-125742-0_CMC-Review-Memo-August-21-2021-COMIRNATY.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/11/109_Courtesy-Copy_2_BLA-125742-0_CMC-Review-Memo-August-21-2021-COMIRNATY.pdf) |
| `62_BLA-125742-0_08-12-2021_Memo_Committee-Memo_Requir.pdf` | Individual | Pfizer | — | 2 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/11/62_BLA-125742-0_08-12-2021_Memo_Committee-Memo_Requir.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/11/62_BLA-125742-0_08-12-2021_Memo_Committee-Memo_Requir.pdf) |
| `125752_S55_M1_pbrer-2-01jul2021-31dec2021.pdf` | M1 | Moderna | BLA | 5361, 5555, 5605 | [PHMPT zip](https://mdata0612.s3.us-east-2.amazonaws.com/mdocs/multiple/md-production-063025.zip) |
| `125742_S1_M5_CRF_c4591001-1092-10921208.pdf` | M5 | Pfizer | BLA | 168 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/07/125742_S1_M5_CRF_c4591001-1092-10921208.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/07/125742_S1_M5_CRF_c4591001-1092-10921208.pdf) |
| `125752_S3_M5_CRF_mrna-1273-p301-us3032172.pdf` | M5 | Moderna | BLA | 771 | [PHMPT](https://phmpt.org/wp-content/uploads/2024/02/125752_S3_M5_CRF_mrna-1273-p301-us3032172.pdf) |
| `125752_S3_M5_CRF_mrna-1273-p301-us3062018.pdf` | M5 | Moderna | BLA | 2102 | [PHMPT](https://phmpt.org/wp-content/uploads/2024/02/125752_S3_M5_CRF_mrna-1273-p301-us3062018.pdf) |

## `(b)(7)(E)` — Law enforcement records — techniques

**38 occurrence(s) across 8 file(s).**

| File | Module | Company | License | Pages | Links |
| --- | --- | --- | --- | --- | --- |
| `108_BLA-125742-0_08-21-2021_Inspection-Related_Inspect.pdf` | Individual | Pfizer | — | 3, 6, 10, 12, 14, 18-19 *(×12 hits)* | [PHMPT](https://phmpt.org/wp-content/uploads/2023/11/108_BLA-125742-0_08-21-2021_Inspection-Related_Inspect.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/11/108_BLA-125742-0_08-21-2021_Inspection-Related_Inspect.pdf) |
| `93_BLA-125752-0_01-26-2022_Inspection-Related_Inspect.pdf` | Individual | Moderna | — | 1-4, 6-7 *(×10 hits)* | [PHMPT](https://phmpt.org/wp-content/uploads/2025/05/93_BLA-125752-0_01-26-2022_Inspection-Related_Inspect.pdf) |
| `120_Courtesy-Copy_BLA-125742-0_CBER-CMC-BLA-Review-Memo-COMIRNATY.pdf` | Individual | Pfizer | — | 11, 50, 66, 124 *(×6 hits)* | [PHMPT](https://phmpt.org/wp-content/uploads/2023/11/120_Courtesy-Copy_BLA-125742-0_CBER-CMC-BLA-Review-Memo-COMIRNATY.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/11/120_Courtesy-Copy_BLA-125742-0_CBER-CMC-BLA-Review-Memo-COMIRNATY.pdf) |
| `100A_BLA-125742-0_08-20-2021_Memo_Other.pdf` | Individual | Pfizer | — | 3 *(×3 hits)* | [PHMPT](https://phmpt.org/wp-content/uploads/2023/11/100A_BLA-125742-0_08-20-2021_Memo_Other.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/11/100A_BLA-125742-0_08-20-2021_Memo_Other.pdf) |
| `100_BLA-125742-0_08-20-2021_Memo_Other.pdf` | Individual | Pfizer | — | 3 *(×3 hits)* | [PHMPT](https://phmpt.org/wp-content/uploads/2023/11/100_BLA-125742-0_08-20-2021_Memo_Other.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/11/100_BLA-125742-0_08-20-2021_Memo_Other.pdf) |
| `118_1_BLA-125742-0_08-22-2021_Inspection-Related_Inspect.pdf` | Individual | Pfizer | — | 1 *(×2 hits)* | [PHMPT](https://phmpt.org/wp-content/uploads/2023/11/118_1_BLA-125742-0_08-22-2021_Inspection-Related_Inspect.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/11/118_1_BLA-125742-0_08-22-2021_Inspection-Related_Inspect.pdf) |
| `109_Courtesy-Copy_2_BLA-125742-0_CMC-Review-Memo-August-21-2021-COMIRNATY.pdf` | Individual | Pfizer | — | 52 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/11/109_Courtesy-Copy_2_BLA-125742-0_CMC-Review-Memo-August-21-2021-COMIRNATY.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/11/109_Courtesy-Copy_2_BLA-125742-0_CMC-Review-Memo-August-21-2021-COMIRNATY.pdf) |
| `62_BLA-125742-0_08-12-2021_Memo_Committee-Memo_Requir.pdf` | Individual | Pfizer | — | 2 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/11/62_BLA-125742-0_08-12-2021_Memo_Committee-Memo_Requir.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/11/62_BLA-125742-0_08-12-2021_Memo_Committee-Memo_Requir.pdf) |

## `(b)(2)` — Internal personnel rules and practices

**26 occurrence(s) across 12 file(s).**

| File | Module | Company | License | Pages | Links |
| --- | --- | --- | --- | --- | --- |
| `12_BLA-125742-0_07-01-2021_Memo_Filing-Checklist_RPM.pdf` | Individual | Pfizer | — | 1, 17 *(×4 hits)* | [PHMPT](https://phmpt.org/wp-content/uploads/2023/09/12_BLA-125742-0_07-01-2021_Memo_Filing-Checklist_RPM.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/09/12_BLA-125742-0_07-01-2021_Memo_Filing-Checklist_RPM.pdf) |
| `019-ORDER-re-Conduct-an-in-person-Scheduling-Conference-and-submit-a-Joint-Status-Report-by-Jan-27-2023-2023-0.pdf` | Individual | — | — | 4 *(×2 hits)* | [PHMPT](https://phmpt.org/wp-content/uploads/2023/05/019-ORDER-re-Conduct-an-in-person-Scheduling-Conference-and-submit-a-Joint-Status-Report-by-Jan-27-2023-2023-0.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/08/019-ORDER-re-Conduct-an-in-person-Scheduling-Conference-and-submit-a-Joint-Status-Report-by-Jan-27-2023-2023-0.pdf) |
| `125742-45_02-07-2022_Memo_Filing-Checklist_RPM.pdf` | Individual | Pfizer | — | 1, 16 | [PHMPT](https://phmpt.org/wp-content/uploads/2024/01/125742-45_02-07-2022_Memo_Filing-Checklist_RPM.pdf) |
| `017-Answer-2023-01-06.pdf` | Individual | — | — | 21 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/05/017-Answer-2023-01-06.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/08/017-Answer-2023-01-06.pdf) |
| `027-Defendant-Brief-Regarding-Production-Schedule-2023-03-31.pdf` | Individual | — | — | 36 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/05/027-Defendant-Brief-Regarding-Production-Schedule-2023-03-31.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/08/027-Defendant-Brief-Regarding-Production-Schedule-2023-03-31.pdf) |
| `047-PLAINTIFFS-RESPONSE-TO-PFIZER-INC.S-MOTION-FOR-LEAVE-TO-INTERVENE-FOR-A-LIMITED-PURPOSE.pdf` | Individual | Pfizer | — | 15 | [PHMPT](https://phmpt.org/wp-content/uploads/2022/01/047-PLAINTIFFS-RESPONSE-TO-PFIZER-INC.S-MOTION-FOR-LEAVE-TO-INTERVENE-FOR-A-LIMITED-PURPOSE.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2022/03/047-PLAINTIFFS-RESPONSE-TO-PFIZER-INC.S-MOTION-FOR-LEAVE-TO-INTERVENE-FOR-A-LIMITED-PURPOSE.pdf) |
| `94_BLA-125752-0_01-26-2022_Memo_Other.pdf` | Individual | Moderna | — | 2 | [PHMPT](https://phmpt.org/wp-content/uploads/2025/05/94_BLA-125752-0_01-26-2022_Memo_Other.pdf) |
| `125742_S1_M1_meeting-correspondence.pdf` | M1 | Pfizer | BLA | 172, 214, 557, 614, 622 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/10/125742_S1_M1_meeting-correspondence.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/10/125742_S1_M1_meeting-correspondence.pdf) |
| `125742_S1_M1_356h.pdf` | M1 | Pfizer | BLA | 1, 3 *(×3 hits)* | [PHMPT](https://phmpt.org/wp-content/uploads/2022/03/125742_S1_M1_356h.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2022/03/125742_S1_M1_356h.pdf) |
| `125742_S2_M1_356h.pdf` | M1 | Pfizer | BLA | 1, 3 *(×3 hits)* | [PHMPT](https://phmpt.org/wp-content/uploads/2023/10/125742_S2_M1_356h.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/10/125742_S2_M1_356h.pdf) |
| `125742_S75_M1_356h.pdf` | M1 | Pfizer | BLA | 1, 3 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/10/125742_S75_M1_356h.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/10/125742_S75_M1_356h.pdf) |
| `125742_S66_M1_pp-cvv-usa-0357.pdf` | M1 | Pfizer | BLA | 149 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/08/125742_S66_M1_pp-cvv-usa-0357.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/08/125742_S66_M1_pp-cvv-usa-0357.pdf) |

## `(b)(4)(D)` — Not a FOIA exemption — likely OCR misread or other-statute reference

**10 occurrence(s) across 6 file(s).**

| File | Module | Company | License | Pages | Links |
| --- | --- | --- | --- | --- | --- |
| `019736_S70_M5_vr-mqr-10211.pdf` | M5 | Pfizer | BLA | 11, 17, 19 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/10/019736_S70_M5_vr-mqr-10211.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/10/019736_S70_M5_vr-mqr-10211.pdf) |
| `019736_S31_M5_vr-mqr-10212.pdf` | M5 | Pfizer | BLA | 15, 28 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/10/019736_S31_M5_vr-mqr-10212.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/10/019736_S31_M5_vr-mqr-10212.pdf) |
| `019736_S31_M5_vr-tm-10293.pdf` | M5 | Pfizer | BLA | 9, 16 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/10/019736_S31_M5_vr-tm-10293.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/10/019736_S31_M5_vr-tm-10293.pdf) |
| `019736_S31_M5_vr-mqr-10214.pdf` | M5 | Pfizer | BLA | 11 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/10/019736_S31_M5_vr-mqr-10214.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/10/019736_S31_M5_vr-mqr-10214.pdf) |
| `125742_S1_M5_5314_vr-mqr-10214.pdf` | M5 | Pfizer | BLA | 20 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/04/125742_S1_M5_5314_vr-mqr-10214.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/04/125742_S1_M5_5314_vr-mqr-10214.pdf) |
| `125752_S3_M5_5314_vsdvac-65-adden-5-v2.pdf` | M5 | Moderna | BLA | 17 | [PHMPT](https://phmpt.org/wp-content/uploads/2024/11/125752_S3_M5_5314_vsdvac-65-adden-5-v2.pdf) |

## `(b)(1)(C)` — Not a FOIA exemption — likely other-statute reference

**6 occurrence(s) across 5 file(s).**

| File | Module | Company | License | Pages | Links |
| --- | --- | --- | --- | --- | --- |
| `125742_S66_M1_pp-cvv-usa-0357.pdf` | M1 | Pfizer | BLA | 137, 144 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/08/125742_S66_M1_pp-cvv-usa-0357.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/08/125742_S66_M1_pp-cvv-usa-0357.pdf) |
| `27073_S1_M1_eua-request-moderna-covid-19-vaccine.pdf` | M1 | Moderna | EUA | 31 | [PHMPT zip](https://mdata0612.s3.us-east-2.amazonaws.com/mdocs/multiple/md-eua-010226.zip) |
| `27073_S3_M1_vrbpac-briefing-doc.pdf` | M1 | Moderna | EUA | 77 | [PHMPT zip](https://mdata0612.s3.us-east-2.amazonaws.com/mdocs/multiple/md-eua-110325.zip) |
| `27073_S8_M1_vrbpac-briefing-doc.pdf` | M1 | Moderna | EUA | 77 | [PHMPT zip](https://mdata0612.s3.us-east-2.amazonaws.com/mdocs/multiple/md-eua-110325.zip) |
| `27073_S1_M2_clinical-overview.pdf` | M2 | Moderna | EUA | 84 | [PHMPT zip](https://mdata0612.s3.us-east-2.amazonaws.com/mdocs/multiple/md-eua-010226.zip) |

## `(b)(7)(A)` — Law enforcement records — ongoing investigations

**2 occurrence(s) across 2 file(s).**

| File | Module | Company | License | Pages | Links |
| --- | --- | --- | --- | --- | --- |
| `125752_S55_M1_pbrer-2-01jul2021-31dec2021.pdf` | M1 | Moderna | BLA | 5339 | [PHMPT zip](https://mdata0612.s3.us-east-2.amazonaws.com/mdocs/multiple/md-production-063025.zip) |
| `125752_S3_M5_CRF_mrna-1273-p301-us3032110.pdf` | M5 | Moderna | BLA | 608 | [PHMPT](https://phmpt.org/wp-content/uploads/2024/02/125752_S3_M5_CRF_mrna-1273-p301-us3032110.pdf) |

## `(b)(8)` — Financial institution information

**1 occurrence(s) across 1 file(s).**

| File | Module | Company | License | Pages | Links |
| --- | --- | --- | --- | --- | --- |
| `125752_S14_M3_32s44_coa-01689-cx-024414-mrna-lot-4007921027.pdf` | M3 | Moderna | BLA | 3 | [PHMPT](https://phmpt.org/wp-content/uploads/2025/05/125752_S14_M3_32s44_coa-01689-cx-024414-mrna-lot-4007921027.pdf) |

## `(b)(1)(B)` — Not a FOIA exemption — likely other-statute reference

**1 occurrence(s) across 1 file(s).**

| File | Module | Company | License | Pages | Links |
| --- | --- | --- | --- | --- | --- |
| `041-Memorandum-in-Support-filed-by-Pfizer-Inc.-re-40-MOTION-to-Intervene-for-a-Limited-Purpose.pdf` | Individual | Pfizer | — | 15 | [PHMPT](https://phmpt.org/wp-content/uploads/2022/01/041-Memorandum-in-Support-filed-by-Pfizer-Inc.-re-40-MOTION-to-Intervene-for-a-Limited-Purpose.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2022/03/041-Memorandum-in-Support-filed-by-Pfizer-Inc.-re-40-MOTION-to-Intervene-for-a-Limited-Purpose.pdf) |

## `(b)(3)` — Information exempt under other statutes

**1 occurrence(s) across 1 file(s).**

| File | Module | Company | License | Pages | Links |
| --- | --- | --- | --- | --- | --- |
| `041-Memorandum-in-Support-filed-by-Pfizer-Inc.-re-40-MOTION-to-Intervene-for-a-Limited-Purpose.pdf` | Individual | Pfizer | — | 15 | [PHMPT](https://phmpt.org/wp-content/uploads/2022/01/041-Memorandum-in-Support-filed-by-Pfizer-Inc.-re-40-MOTION-to-Intervene-for-a-Limited-Purpose.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2022/03/041-Memorandum-in-Support-filed-by-Pfizer-Inc.-re-40-MOTION-to-Intervene-for-a-Limited-Purpose.pdf) |

## `(b)(9)` — Geological / geophysical information

**1 occurrence(s) across 1 file(s).**

| File | Module | Company | License | Pages | Links |
| --- | --- | --- | --- | --- | --- |
| `111521-Second-Joint-Status-Report.pdf` | Individual | Pfizer | — | 2 | [PHMPT](https://phmpt.org/wp-content/uploads/2021/11/111521-Second-Joint-Status-Report.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2022/03/111521-Second-Joint-Status-Report.pdf) |

## `(b)(13)` — Not a FOIA exemption — FOIA has only (b)(1)-(b)(9)

**1 occurrence(s) across 1 file(s).**

| File | Module | Company | License | Pages | Links |
| --- | --- | --- | --- | --- | --- |
| `12_BLA-125742-0_07-01-2021_Memo_Filing-Checklist_RPM.pdf` | Individual | Pfizer | — | 12 | [PHMPT](https://phmpt.org/wp-content/uploads/2023/09/12_BLA-125742-0_07-01-2021_Memo_Filing-Checklist_RPM.pdf) · [ICAN](https://icandecide.org/wp-content/uploads/2023/09/12_BLA-125742-0_07-01-2021_Memo_Filing-Checklist_RPM.pdf) |